Challenge in Treating Patients With Multiple Myeloma
Ajai Chari, MD, discusses the biggest challenge in treating patients with multiple myeloma.
Ajai Chari, MD, associate professor of medicine at the Mount Sinai School of Medicine, discusses the biggest challenge in treating patients with multiple myeloma.
The treatment landscape is very exciting, Chari says. Ten drugs have been approved over the last decade, while 4 of those were approved in 2015. However, the biggest challenge now with these patients is what happens when patients exhaust these options.
Patients who are penta-refractory are refractory to 5 of these currently approved therapies. The question is then what to do for these patients who have seemingly exhausted all options, Chari concludes.
At the 2018 ASH Annual Meeting,data from part 2 of the pivotal STORM trial
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
